---
title: 'Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on
  Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy
  Volunteers'
date: '2025-01-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39861708/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250126170510&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Background/Objectives: Bempedoic acid (BA) is a novel cholesterol-lowering
  agent with proven positive effects on cardiovascular endpoints. Because it is an
  inhibitor of the hepatic transporters OATP1B1 and OATP1B3, two uptake transporters
  regulating the intrahepatic availability of statins, it increases the systemic exposure
  of co-administered statins. This interaction could raise the risk of myopathy. We
  hypothesized that the drug interaction between BA and statins could be mitigated
  ...'
disable_comments: true
---
Background/Objectives: Bempedoic acid (BA) is a novel cholesterol-lowering agent with proven positive effects on cardiovascular endpoints. Because it is an inhibitor of the hepatic transporters OATP1B1 and OATP1B3, two uptake transporters regulating the intrahepatic availability of statins, it increases the systemic exposure of co-administered statins. This interaction could raise the risk of myopathy. We hypothesized that the drug interaction between BA and statins could be mitigated ...